MAPT and Alzheimer disease: C004019 was shown to degrade tau in a mouse model expressing human wild-type tau, reduced tau levels and rescued cognitive and synaptic phenotypes in the 3xTg AD mice, providing the first proof for in vivo efficacy [105].